Evidence map›Paper›PMID 29725069›Full record

ArticleScientific reports2018

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation.

Toshiki Kijima, Thomas L Prince, Megan L Tigue, Kendrick H Yim, Harvey Schwartz, Kristin Beebe, Sunmin Lee, Marek A Budzynski, Heinric Williams, Jane B Trepel and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 144 citations in OpenAlex.

  1. Article
  2. Hsp90: A means to an end.Cell stress & chaperones · 2026
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Function and regulation of the mitochondrial stress response.Nature structural & molecular biology · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Identification of novel small molecule chaperone activators for neurodegenerative disease treatment.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025
    Article
  15. Review
  16. Article
  17. Article
  18. HSF1 Activation Mechanisms, Disease Roles, and Small Molecule Therapeutics.International journal of biological sciences · 2025
    Review
  19. Article
  20. Transcriptomic Analysis of the CAM SpeciesPlants (Basel, Switzerland) · 2024
    Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Toshiki KijimaUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Thomas L PrinceUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States. tprince@geisinger.edu.
Megan L TigueUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Kendrick H YimUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Harvey SchwartzUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Kristin BeebeUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Sunmin LeeDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Marek A BudzynskiFaculty of Science and Engineering, Cell Biology, Åbo Akademi University, BioCity, Tykistökatu 6, Turku, FIN-20520, Finland.
Heinric WilliamsUrology Department, Geisinger Clinic, WCR 221, Danville, PA, 17821, United States.
Jane B TrepelDevelopmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States.
Lea SistonenFaculty of Science and Engineering, Cell Biology, Åbo Akademi University, BioCity, Tykistökatu 6, Turku, FIN-20520, Finland.
Stuart CalderwoodRadiation Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA, 02215, United States.
Len NeckersUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, United States. neckersl@mail.nih.gov.
National Institutes of Health · USCenter for Cancer Research · USÅbo Akademi University · FINational Cancer Institute · USBeth Israel Deaconess Medical Center · USGeisinger Medical Center · US

Funding

Signal Transduction Events and the Regulation of Cell GrowthZICSC006743 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI TREPEL, JANE B · 2009 to 2023
$13.8M
Role of HSP90 Family Chaperone Proteins in Cellular Signal TransductionZIASC010074 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI NECKERS, LEONARD · 2009 to 2025
$13.3M
TRANSMEMBRANE SIGNAL MODULATION BY HYPERTHERMIAR01CA047407 · NCI · DANA-FARBER CANCER INSTITUTE · PI CALDERWOOD, STUART KEITH · 1988 to 2014
$4.3M
Complex Role of HSF1 in Breast CancerR01CA176326 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CALDERWOOD, STUART KEITH, SHERMAN, MICHAEL Y · 2014 to 2018
$1.8M
NCI NIH HHS R01 CA047407NCI NIH HHS R01 CA176326
6 · The paper itself

Abstract

Heat shock factor 1 (HSF1) initiates a broad transcriptional response to proteotoxic stress while also mediating a cancer-specific transcriptional program. HSF1 is thought to be regulated by molecular chaperones, including Heat Shock Protein 90 (HSP90). HSP90 is proposed to sequester HSF1 in unstressed cells, but visualization of this interaction in vivo requires protein crosslinking. In this report, we show that HSP90 binding to HSF1 depends on HSP90 conformation and is only readily visualized for the ATP-dependent, N-domain dimerized chaperone, a conformation only rarely sampled by mammalian HSP90. We have used this mutationally fixed conformation to map HSP90 binding sites on HSF1. Further, we show that ATP-competitive, N-domain targeted HSP90 inhibitors disrupt this interaction, resulting in the increased duration of HSF1 occupancy of the hsp70 promoter and significant prolongation of both the constitutive and heat-induced HSF1 transcriptional activity. While our data do not support a role for HSP90 in sequestering HSF1 monomers to suppress HSF1 transcriptional activity, our findings do identify a noncanonical role for HSP90 in providing dynamic modulation of HSF1 activity by participating in removal of HSF1 trimers from heat shock elements in DNA, thus terminating the heat shock response.

Indexed as

Gene Expression RegulationBinding SitesDNAEnzyme InhibitorsHeat Shock Transcription FactorsHEK293 CellsHSP90 Heat-Shock ProteinsHumansPromoter Regions, GeneticProtein BindingDNAEnzyme InhibitorsHeat Shock Transcription FactorsHSF1 protein, humanHSP90AA1 protein, humanHSP90AB1 protein, humanHSP90 Heat-Shock Proteins

Identifiers

PMID29725069
PMCPMC5934406
OpenAlexW2903378613

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.